Heart failure drug withdrawal trial aims to simplify treatment
NCT ID NCT07489547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with stable heart failure whose heart function has improved can safely stop taking a type of medication called a mineralocorticoid antagonist (MRA). Researchers will monitor 90 participants over 24 weeks to see if stopping the drug leads to a decline in heart function or other health issues. The goal is to find out if it's safe to simplify treatment for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital de Clínicas de Porto Alegre
RECRUITINGPorto Alegre, Rio Grande do Sul, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?